HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.

Abstract
Pancreatic adenocarcinoma is one of the malignancies that is highly resistant to therapy and among the leading causes of cancer-related death. Several factors may influence pancreatic cancer resistance, and expression of ATP-binding cassette transport proteins is one of the major mechanisms of drug resistance. Members of this family's C-branch, also referred to as multidrug resistance-associated proteins (MRPs), might be of particular interest because they are able to efflux nucleoside analogs used in the treatment of pancreatic cancer. Expression of MRP1, MRP3, MRP4, and MRP5 in human pancreas and pancreatic carcinoma has been reported. However, contributions of MRPs to chemoresistance of pancreatic cancer are not fully understood. MRP5 mRNA expression in pancreatic adenocarcinoma cell lines correlated significantly with cellular sensitivity to 5-fluorouracil (5-FU) (r = 0.738, p < 0.05). Long-term treatment with 5-FU increased expression of MRP5 by 2.4-fold and was associated with significant drug resistance [IC(50) values for control and 5-fluorouracil (5-FU)-resistant Patu-T cell lines were 11.3 ± 5.3 and 33.2 ± 6.9 μM, respectively (p < 0.05)]. Consequently, overexpression of MRP5 in Colo-357 cells resulted in significantly reduced accumulation of 5-FU related radioactivity and 5-FU cytotoxicity. Knockdown of MRP5 significantly increased cellular cytotoxicity of 5-FU to Patu-02 cells and enhanced accumulation of radioactivity related to 5-FU and its metabolites. Our results suggest that MRP5 is expressed and functionally active and contributes to variable sensitivities of pancreatic adenocarcinoma cell lines to 5-FU. Further investigations using models that resemble human pancreas tumors are necessary to prove a causative relation between expression and activity of MRP5 and tumor resistance to 5-FU.
AuthorsPraveen K Nambaru, Tobias Hübner, Kathleen Köck, Steffen Mews, Markus Grube, Léa Payen, Jérôme Guitton, Matthias Sendler, Gabriele Jedlitschky, Christian Rimmbach, Dieter Rosskopf, Dariusz W Kowalczyk, Heyo K Kroemer, Frank U Weiss, Julia Mayerle, Markus M Lerch, Christoph A Ritter
JournalDrug metabolism and disposition: the biological fate of chemicals (Drug Metab Dispos) Vol. 39 Issue 1 Pg. 132-9 (Jan 2011) ISSN: 1521-009X [Electronic] United States
PMID20930123 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • ABCC5 protein, human
  • Antimetabolites, Antineoplastic
  • Multidrug Resistance-Associated Proteins
  • RNA
  • Fluorouracil
Topics
  • Adenocarcinoma
  • Antimetabolites, Antineoplastic (pharmacology)
  • Cell Line, Tumor
  • Drug Resistance, Multiple (genetics)
  • Drug Resistance, Neoplasm (genetics)
  • Fluorouracil (pharmacology)
  • Gene Knockdown Techniques
  • Humans
  • Multidrug Resistance-Associated Proteins (metabolism)
  • Pancreas (metabolism)
  • Pancreatic Neoplasms (drug therapy, metabolism)
  • RNA (analysis)
  • RNA Interference
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: